WC
SAGE

Wexford Capital’s Sage Therapeutics SAGE Stock Holding History

Wexford Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,400
Closed -$350K – 184
2017
Q2 		$350K Buy
+4,400
New +$318K 0.03% 138
2016
Q3 		– Sell
-30,396
Closed -$916K – 180
2016
Q2 		$916K Hold
30,396
– – 0.16% 76
2016
Q1 		$974K Buy
+30,396
New +$1.07M 0.19% 78

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wexford Capital's SAGE Position: Q3 2017 in Review

Wexford Capital sold out of Sage Therapeutics (SAGE) in Q3 2017, closing a stake of 4,400 shares — an estimated $350K sold.

Wexford Capital first reported a position in SAGE in Q1 2016 and held it in 3 quarters. The position peaked at $974K in Q1 2016. 174 funds tracked by Wall St. Rank hold SAGE as of Q3 2017.

  • Wexford Capital reported no remaining Sage Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Wexford Capital sold 4,400 Sage Therapeutics shares in Q3 2017, an estimated $350K.
  • Wexford Capital first reported a position in Sage Therapeutics in Q1 2016 and held it in 3 quarters.
  • Wexford Capital's Sage Therapeutics position peaked at $974K in Q1 2016.
  • 174 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2017.

Based on Wexford Capital's 13F filing for Q3 2017, filed 13 Nov 2017.